CY1113283T1 - Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων - Google Patents

Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων

Info

Publication number
CY1113283T1
CY1113283T1 CY20121100798T CY121100798T CY1113283T1 CY 1113283 T1 CY1113283 T1 CY 1113283T1 CY 20121100798 T CY20121100798 T CY 20121100798T CY 121100798 T CY121100798 T CY 121100798T CY 1113283 T1 CY1113283 T1 CY 1113283T1
Authority
CY
Cyprus
Prior art keywords
phosphomycin
combination
tobramycin
tombramycin
aerofilated
Prior art date
Application number
CY20121100798T
Other languages
English (en)
Inventor
William Baker
David Macleod
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1113283T1 publication Critical patent/CY1113283T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Περιγράφεται μια φαρμακοτεχνική μορφή συνδυασμού φωσφομυκίνης και τομπραμυκίνης για απελευθέρωση μέσω αερολυματοποίησης. Η συμπυκνωμένη φαρμακοτεχνική μορφή συνδυασμού φωσφομυκίνης τομπραμυκίνης περιέχουσα μία αποτελεσματική ποσότητα φωσφομυκίνης και τομπραμυκίνης είναι σε θέση να αναστείλει τα ευεπηρέαστα βακτηρίδια. Η φωσφομυκίνη και η τομπραμυκίνη τυποποιούνται παρασκευαστικώς ξεχωριστά μέσα σε μία διπλή φύσιγγα έτσι ώστε όταν ανασυσταίνονται, το pΗ να είναι μεταξύ 4.5 και 8.0 ή ως μία ξηρά κόνις. Η μέθοδος για αγωγή των λοιμώξεων της αναπνευστικής οδού μέσω μιας φαρμακοτεχνικής μορφής που απελευθερώνεται ως ένα αερόλυμα έχον μέση κατά μέσο όρο διάμετρο μάζας που είναι επικρατέστερα μεταξύ 1 έως 5 μ, παράγεται μέσω ενός νεφελοποιητή αεριώθησης ή υπερηχητικό νεφελοποιητή (ή ισοδύναμο) ή εισπνευστήρα ξηρών κόνεων.
CY20121100798T 2004-05-17 2012-09-05 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων CY1113283T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57173904P 2004-05-17 2004-05-17
US65900505P 2005-03-03 2005-03-03
EP10182347A EP2316419B1 (en) 2004-05-17 2005-05-02 Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections

Publications (1)

Publication Number Publication Date
CY1113283T1 true CY1113283T1 (el) 2016-04-13

Family

ID=35394588

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100268T CY1112004T1 (el) 2004-05-17 2011-03-09 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/αμινογλυκοζιτη για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
CY20121100798T CY1113283T1 (el) 2004-05-17 2012-09-05 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
CY20121101067T CY1113319T1 (el) 2004-05-17 2012-11-09 Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100268T CY1112004T1 (el) 2004-05-17 2011-03-09 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/αμινογλυκοζιτη για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121101067T CY1113319T1 (el) 2004-05-17 2012-11-09 Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης

Country Status (19)

Country Link
US (4) US7943118B2 (el)
EP (3) EP1750667B1 (el)
JP (1) JP4745340B2 (el)
AR (1) AR048793A1 (el)
AT (1) ATE493969T1 (el)
AU (2) AU2005244153B2 (el)
BR (1) BRPI0509026A (el)
CA (1) CA2564546C (el)
CY (3) CY1112004T1 (el)
DE (1) DE602005025754D1 (el)
DK (3) DK2266534T3 (el)
ES (3) ES2358024T3 (el)
HK (2) HK1151191A1 (el)
IL (2) IL179277A (el)
PL (3) PL2266534T3 (el)
PT (3) PT1750667E (el)
SI (3) SI2316419T1 (el)
TW (1) TWI409074B (el)
WO (1) WO2005110022A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750667E (pt) 2004-05-17 2011-03-11 Corus Pharma Inc Combinação aerossolizada de fosfomicina/aminoglicósido para o tratamento de infecções respiratórias bacterianas
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ES2666276T3 (es) * 2006-10-11 2018-05-03 Laboratoires Smb Sa Composición farmacéutica antiinfecciosa para inhalación
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
EP2349278A1 (en) * 2008-10-21 2011-08-03 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
AU2010324997A1 (en) * 2009-11-24 2012-05-31 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
WO2011087799A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CA2812044A1 (en) * 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) * 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
MX2014000540A (es) * 2011-07-12 2014-05-01 Cardeas Pharma Corp Formulaciones de combinaciones de amecacina y forsfomicina y metodos y sistemas para el tratamiento de neumonia asociada a ventilacion mecanica (vap) y traqueobronquitis asociada a ventilacion mecanica (vat).
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
EP2567691B1 (en) * 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Aqueous compositions comprising arbekacin
MX2016002524A (es) * 2013-08-26 2016-10-26 Cardeas Pharma Corp Formulaciones de aminoglucosidos y fosfomicina en una combinacion que tiene propiedades quimicas mejoradas.
EP3219305A1 (de) 2016-03-16 2017-09-20 Apostolos Georgopoulos Fosfomycin-formulierung zur parenteralen verabreichung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750919A (en) 1980-09-16 1982-03-25 Meiji Seika Kaisha Ltd Agent for reducing side effect
JPS58134028A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) * 1991-02-15 1991-04-03 Waverley Pharma Ltd Transfer adaptor
US5488038A (en) * 1992-11-27 1996-01-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JPH09183730A (ja) 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999017782A1 (fr) * 1997-10-03 1999-04-15 Meiji Seika Kaisha Ltd. Composition pour le traitement du diabete et procede de traitement du diabete
BR9916296A (pt) * 1998-12-17 2004-06-29 Pathogenesis Corp Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002258563A1 (en) 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
JP2004534763A (ja) * 2001-05-18 2004-11-18 カイロン コーポレイション アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
US20040247628A1 (en) 2001-10-24 2004-12-09 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
PT1750667E (pt) 2004-05-17 2011-03-11 Corus Pharma Inc Combinação aerossolizada de fosfomicina/aminoglicósido para o tratamento de infecções respiratórias bacterianas
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2008071197A1 (en) 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
US20090054374A1 (en) 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2010324997A1 (en) 2009-11-24 2012-05-31 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
PT1750667E (pt) 2011-03-11
EP1750667A2 (en) 2007-02-14
EP2266534B1 (en) 2012-09-26
US20070218013A1 (en) 2007-09-20
ES2388420T3 (es) 2012-10-15
US20110189103A1 (en) 2011-08-04
PT2266534E (pt) 2012-10-09
DK1750667T3 (da) 2011-04-26
AU2009243536B2 (en) 2012-03-22
PL2316419T3 (pl) 2012-12-31
ES2392389T3 (es) 2012-12-10
JP4745340B2 (ja) 2011-08-10
EP2316419A1 (en) 2011-05-04
AU2009243536A1 (en) 2009-12-24
DK2266534T3 (da) 2013-01-14
US7943118B2 (en) 2011-05-17
EP2266534A1 (en) 2010-12-29
EP1750667B1 (en) 2011-01-05
IL179277A (en) 2013-04-30
TW200608983A (en) 2006-03-16
PT2316419E (pt) 2012-10-22
US20130071442A1 (en) 2013-03-21
ES2358024T3 (es) 2011-05-04
EP1750667A4 (en) 2007-07-11
SI2316419T1 (sl) 2012-10-30
WO2005110022A2 (en) 2005-11-24
DK2316419T3 (da) 2012-10-22
PL1750667T3 (pl) 2011-06-30
HK1151191A1 (en) 2012-01-27
EP2316419B1 (en) 2012-07-11
AR048793A1 (es) 2006-05-24
CA2564546A1 (en) 2005-11-24
TWI409074B (zh) 2013-09-21
SI1750667T1 (sl) 2011-04-29
US8361444B2 (en) 2013-01-29
US8409549B2 (en) 2013-04-02
HK1157637A1 (en) 2012-07-06
AU2005244153B2 (en) 2009-10-29
CY1113319T1 (el) 2016-04-13
AU2005244153A1 (en) 2005-11-24
ATE493969T1 (de) 2011-01-15
SI2266534T1 (sl) 2012-12-31
CY1112004T1 (el) 2015-11-04
PL2266534T3 (pl) 2013-02-28
US8980226B2 (en) 2015-03-17
IL225529A (en) 2014-08-31
WO2005110022A3 (en) 2006-04-06
BRPI0509026A (pt) 2007-09-18
IL179277A0 (en) 2007-05-15
IL225529A0 (en) 2013-06-27
DE602005025754D1 (de) 2011-02-17
JP2007538075A (ja) 2007-12-27
CA2564546C (en) 2013-02-26
US20110117030A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
CY1113283T1 (el) Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
ECSP077182A (es) Metodos para el tratamiento de infecciones endobronquiales
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
NZ515392A (en) Respiratory syncytial virus replication inhibitors
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2007008825A3 (en) System and method for optimized delivery of an aerosol to the respiratory tract
ATE430154T1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
EP1838303A4 (en) USE OF DIINDOLYLMETHAN-RELATED INDOLAS FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS
CY1114728T1 (el) Φαρμακοτεχνικη μορφη εισπνοης περιλαμβανουσα παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
WO2009110940A3 (en) Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use
WO2009086470A3 (en) Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
ECSP066608A (es) Suspensiones acuosas de ciclesonide para nebulización
DE502005005498D1 (de) Verfahren zur Herstellung fester Treibmittelpräparationen
BRPI0512563B8 (pt) uso de compostos na preparação de um medicamento para o tratamento profilático e/ou terapêutico de infecções bacterianas
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
WO2008051304A3 (en) Treatment of airflow
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
BR0112330A (pt) Formulações de macrolìdeos para inalação e seus usos para o tratamento de infecções endobrÈnquicas
WO2002065972A3 (de) Verfahren zur desinfektion von frischluft, luftdesinfektionsmodul, cpap-gerät, luftbefeuchter, beatmungsgerät, blitzlampe sowie gasentladungslampe
EP1305042A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS
TW200503716A (en) Treatment of bacterial diseases of the respiratory organs
DE60213232D1 (de) Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
GB2405338A (en) Method of prophylaxis of infection
MXPA05010629A (es) Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas.